BioLife Solutions (NASDAQ:BLFS – Get Free Report) and Cytosorbents (NASDAQ:CTSO – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations and profitability.
Institutional & Insider Ownership
93.2% of BioLife Solutions shares are held by institutional investors. Comparatively, 32.9% of Cytosorbents shares are held by institutional investors. 2.2% of BioLife Solutions shares are held by company insiders. Comparatively, 6.6% of Cytosorbents shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares BioLife Solutions and Cytosorbents’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioLife Solutions | -3.20% | 0.97% | 0.87% |
| Cytosorbents | -27.77% | -101.14% | -24.38% |
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioLife Solutions | $82.25 million | 14.85 | -$20.18 million | ($0.07) | -362.43 |
| Cytosorbents | $35.60 million | 1.35 | -$20.72 million | ($0.18) | -4.25 |
BioLife Solutions has higher revenue and earnings than Cytosorbents. BioLife Solutions is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
BioLife Solutions has a beta of 1.93, indicating that its share price is 93% more volatile than the S&P 500. Comparatively, Cytosorbents has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for BioLife Solutions and Cytosorbents, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioLife Solutions | 1 | 0 | 5 | 1 | 2.86 |
| Cytosorbents | 1 | 1 | 1 | 0 | 2.00 |
BioLife Solutions currently has a consensus price target of $31.20, suggesting a potential upside of 22.98%. Cytosorbents has a consensus price target of $5.38, suggesting a potential upside of 601.88%. Given Cytosorbents’ higher probable upside, analysts clearly believe Cytosorbents is more favorable than BioLife Solutions.
Summary
BioLife Solutions beats Cytosorbents on 12 of the 14 factors compared between the two stocks.
About BioLife Solutions
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
About Cytosorbents
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.
